Bausch Health Companies Inc Stock Price, News & Analysis

KBRA has published its First-Quarter 2022 U.S. Bank Compendium, offering insights into the banking sector's performance. The report highlights the impact of inflation on vehicle prices and auto loan exposures within the KBRA-rated banks. It includes summaries of 1Q22 results for publicly traded U.S. banks, focusing on key performance metrics and credit ratios. Additionally, the Compendium features the top 10 low-cost deposit franchises and a detailed supplement of 171 debt issues rated by KBRA.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its participation in investor conferences, including the Goldman Sachs Leveraged Finance and Credit Conference on May 12, 2022, and the Barclays High Yield Bond & Syndicated Loan Conference on May 24, 2022. Key executives such as Tom Vadaketh and Christina Cheng will represent the company. Live webcasts of these events will be accessible on the Investor Relations page of their website. Bausch Health focuses on enhancing global health through a diverse range of pharmaceutical products.

Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) reported first-quarter 2022 revenues of $1.918 billion, a 5% decrease from $2.027 billion in Q1 2021. Despite challenges, organic growth remained stable year-over-year. The company recorded a GAAP net loss of $69 million, an improvement from a $610 million loss in the same quarter last year. Adjusted EBITDA fell to $732 million, down from $852 million. Bausch + Lomb has begun trading under the 'BLCO' ticker following its IPO, which is expected to generate $630 million to reduce long-term debt. The full-year revenue guidance is set between $8.25 billion and $8.4 billion.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Thomas J. Appio as CEO and announced its leadership team and Board of Directors. Following the IPO of Bausch + Lomb, Joseph C. Papa will transition to chairman and CEO of Bausch + Lomb. The new executive team comprises experienced leaders, including Thomas Vadaketh as CFO and Seana Carson as General Counsel. Richard Mulligan, Ph.D., was appointed to the Board. The full separation of Bausch + Lomb is expected to finalize on May 10, 2022, with shares trading under the symbol 'BHC'.

Bausch + Lomb Corporation, a subsidiary of Bausch Health (NYSE/TSX: BHC), has announced the pricing of its initial public offering (IPO) of 35 million common shares at $18.00 each. Bausch + Lomb will not receive the proceeds from this offering, as it is being conducted by the Selling Shareholder. The shares are set to trade on the NYSE and TSX under the ticker symbol 'BLCO' starting May 6, 2022. Following the IPO, Bausch Health will retain around 90% of Bausch + Lomb's shares, decreasing to 88.5% if the underwriters' over-allotment option is fully exercised.

Bausch Health and Novaliq announced that their investigational treatment NOV03 successfully met primary endpoints in two pivotal Phase 3 trials for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The latest trial results demonstrated significant improvements in total corneal fluorescein staining and eye dryness scores at day 57. With potential FDA submission in Q2 2022, NOV03 could become the first pharmaceutical therapy available in the U.S. targeting this common ocular condition affecting approximately 18 million Americans.

Bausch Health Companies (NYSE/TSX: BHC) will announce its first-quarter financial results on May 10, 2022. A conference call and live webcast will be held at 8:00 a.m. ET to discuss these results and provide a business update. Investors can access materials through the Investor Relations section of the Bausch Health website before the call.

Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies (NYSE/TSX: BHC), has announced its initial public offering (IPO), offering 35 million common shares with an expected price range of $21 to $24 per share. A 30-day option for underwriters to purchase an additional 5.25 million shares is also planned. Post-IPO, Bausch Health will hold approximately 90% of Bausch + Lomb's shares. The IPO aims for listing on the NYSE and TSX under the ticker symbol 'BLCO'. Bausch + Lomb will not receive any IPO proceeds.